REDWOOD CITY, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the third quarter of 2025 on Wednesday, November 5, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines’ senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.
To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live webcast, a replay will be available on the company’s website for at least 14 days.
About Revolution Medicines, Inc.
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are currently in clinical development. The company anticipates that RMC-5127, a RAS(ON) G12V-selective inhibitor, will be its next RAS(ON) inhibitor to enter clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com and follow us on LinkedIn.
Revolution Medicines Media & Investor Contact:
media@revmed.com
investors@revmed.com

| 1 hour | |
| 2 hours | |
| Nov-09 |
Trump's Plan to Lower Drug Prices in U.S. Is Leading to Fewer New Drugs in Europe
RVMD
The Wall Street Journal
|
| Nov-05 | |
| Nov-05 | |
| Nov-05 |
Biotech Earnings: Who Won, Who Lost And Who Pulled Off A 'Historic' Launch?
RVMD -11.04%
Investor's Business Daily
|
| Nov-04 | |
| Nov-04 | |
| Oct-29 | |
| Oct-27 | |
| Oct-27 | |
| Oct-27 | |
| Oct-25 |
ESMO26: Clinical progress shifts a historically difficult pancreatic cancer landscape
RVMD
Clinical Trials Arena
|
| Oct-23 | |
| Oct-23 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, alerts, and much more.
Learn more about Finviz Elite